Korean J Med.
2013 Apr;84(4):613-618.
A Case of Systemic Lupus Erythematosus-Associated Hemophagocytic Lymphohistiocytosis Treated Successfully with an Etoposide Infusion
- Affiliations
-
- 1Department of Internal Medicine, Seoul Veterans Hospital, Seoul, Korea. schenics@naver.com
Abstract
- Hemophagocytic lymphohistiocytosis (HLH) can develop following strong activation of the immune system and the cardinal symptoms are a prolonged fever, hematological abnormalities, hepatosplenomegaly, and hemophagocytosis. HLH can be classified as primary or secondary HLH, associated with infections, malignancy and autoimmune disease. There is no consensus on the primary treatment regimen in systemic lupus erythematosus (SLE)-associated HLH. We experienced a case of SLE-associated HLH in a previously healthy adult. She was initially treated with intravenous immunoglobulin, cyclosporine, and high-dose steroid, but had a poor clinical response. After intravenous etoposide, the patient stabilized and has been followed for 1 year without reactivation of the HLH or SLE.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- A Case of Hemophagocytic Lymphohistiocytosis in a Child with Systemic Lupus Erythematosus
- Three Cases of Secondary Hemophagocytic Lymphohistiocytosis Associated with Systemic Erythematosus Lupus
- Refractory Macrophage Activation Syndrome in a Patient with Systemic Lupus Erythematosus Treated with Tocilizumab
- A Case of Secondary Precursor B-cell Acute Lymphoblastic Leukemia Occurring after Treatment of Hemophagocytic Lymphohistiocytosis
- A Case of Subcutaneous Panniculitic T-cell Lymphoma-like Lesion Occurring in a Patient with Systemic Lupus Erythematosus
